Technical Data
Brain Derived Neurotrophic Factor (BDNF)
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer’s, and Parkinson’s disease. Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB.

Suitable for use in ELISA, Western Blot, Inhibition and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: 1-10ug/ml
Western Blot, Dot Blot: 1-10ug/ml
ELISA: 0.1ug/ml
Inhibition: 1-10ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
500ug-20°CBlue IceHumanRabbit
Recombinant human BDNF.
Purified by affinity chromatography.
Supplied as a lyophilized powder. Reconstitute in 500ul of sterile ddH2O. Centrifuge to remove any insoluble material.
Recognizes human Brain Derived Neurotrophic Factor. <0.1% crossreactivity against NGF, recombinant NT3 and NT4 by Dot Blot. Species Crossreactivity: rat and mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. A Acheson et al (1995) Nat. 74: 450-3 ; 2. Q Yan et al (1994) J. Neurosci. 14(9): 5281-91 ; 3. XF Zhou et al (1996) Neurosci. 74: 945-53 ; 4. XF Zhou, et al (1998) Exp. Neurol. 149: 237-42 ; 5. B Mellstrom et al (2004) Crit Rev Neurobiol 16, 43-9 ; 6. Tapia-Arancibia et al (2004) Front Neuroendocrinol 25, 77-107 ; 7. S Pezet, et al (2002) Brain Res Brain Res Rev 40, 240-9 ; 8. Barde Y. A. et al (1989) EMBO J. 1: 549 ; 9. Conner J et al. (1997) J. Neurosci. 17: 2295